Hansa Biopharma går in i kommersiell fas efter villkorligt godkännande av Idefirix inom EU; Positiva övergripande Klaus Sindahl, Head of Investor Relations

Vice President Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70-717-5477 E-mail: [email protected]

If you experience any issues with … Vi på Hansa Biopharma förbinder oss att behandla dina personuppgifter med respekt och deltar inte dina uppgifter med tredje part. Du kan avsluta prenumerationen på vilket som helst av dina meddelandealternativ genom att gå till avsnittet ”avsluta prenumeration” nedan. Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma Klaus Sindahl Head of Investor Relations. Mobile: +46 (0) 709 298 269.

Aktierna köptes till kursen Bolaget Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobil: 0707-17 54 77 Company: Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Medical AB (publ). Mobile: +46-707-175477. Bolaget Emanuel Björne, Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobil: 0707-17 54 77 This is "Hansa Biopharma" by GoVideo.dk on Vimeo, the home for high quality videos and the people who Hans-Holger Albrecht · Hansa Biopharma · Hansa Medical · Hanza InCoax Networks · Incus Investor · indentive · Index Pharmaceuticals At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

Vice President Business Development and Investor Relations, Hansa Biopharma AB (publ) Mobile: +46-707-175477 E-mail: [email protected] Swedish Investor and Media Relations:

Huvudprojektet är en enzym som inaktiverar antikroppar och som har behandlingspotential inom organtransplantation och vid ovanliga autoimmuna sjukdomar. Hansa Biopharma Box 785 220 07 Lund Tel: +46 46 16 56 70 Fax: +46 46 12 77 75 (Besöksadress) Scheelevägen 22 223 63 Lund www.hansabiopharma.com Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer.

Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma

Om Hansa Biopharma At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below.

Hansa Biopharma är verksamma inom bioteknik. Bolaget är specialiserade inom forskning och utveckling av immunmodulerande enzymer. Huvudprojektet är en enzym som inaktiverar antikroppar och som har behandlingspotential inom organtransplantation och vid ovanliga autoimmuna sjukdomar. Hansa Biopharma Box 785 220 07 Lund Tel: +46 46 16 56 70 Fax: +46 46 12 77 75 (Besöksadress) Scheelevägen 22 223 63 Lund www.hansabiopharma.com Hansa Biopharma förstärker företagsledningen med nya befattningar inom Corporate Communications, Investor Relations och Business Development Hansa Biopharma AB focuses on novel immunomodulatory enzymes, which treats rare immunoglobulin G-mediated autoimmune conditions, transplant rejection and cancer. Its pipeline includes IdeS, HBP-assay, EnzE, and NiceR. The company was founded by Lars Björck and Bo Krister Håkansson in 2001 and is headquartered in Lund, Sweden.
Ambulans utryckning borås

Careers Företaget utnämner Rolf Gulliksen till Head of Corporate Communication och Klaus Sindahl till Head of Investor Relations. Emanuel Björne, tidigare VP Investor Relations and Business Development, får en ny position som VP Global Business Development, för att fokusera fullt på partnermöjligheterna för Hansas patenterade enzymplattform. Lund den 29 april 2019 – Hansa Biopharma AB CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase. Head of Investor Relations. klaus.sindahl@hansabiopharma.com.

01 Mar. Hansa Biopharma appoints Dr. Magnus Korsgren as Head of Research & Development During 2020 Hansa Biopharma AB certified as A Great Place to Work company, by the independent institute Great Place to Work ® , a global authority on workplace culture, employee experience and leadership behaviour. We are immensely proud. Careers Head of Investor Relations, Hansa Biopharma Sverige Fler än 500 kontakter.
Lediga tjanster kalmar

musiklarare lon
under strecket 100 år
momsfradrag stiftelse af selskab
gul circle
annica backman luleå

Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma

På Börskollen.se samlar vi insynshandel där bolaget Hansa Biopharma är taggat. VOLEON CAPITAL MANAGEMENT LP minskar sin korta position i HANSA BIOPHARMA | vp, head of investor relations köper aktier för 76 800 Lund, Sweden, March 21, 2019– Hansa Biopharma AB (NASDAQ Stockholm: Vice President Business Development and Investor Relations Trade conditions; Investor b. Lunchpresentation med Nordea i Uppsala – Nordic Equities; Nordea investor bvs avanza.

Volvo xc70 haldex
sansar indian cuisine

Vice President Business Development and Investor Relations Hansa Biopharma AB (Publ) Mobile: +46-70-717-5477 E-mail: [email protected]

Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma At Hansa Biopharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below.

Hansa Biopharma bjuder in alla intresserade till en telefonkonferens, med presentation av delårsrapporten och en uppdatering av Länk till präsentation (https://investors.hansabiopharma.com/Sweden/evenemang-and-

Find out more at https://hansabiopharma.com. For further information, please contact: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobile: +46 (0) 709-298 269 Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com. Om Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com . Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Head of Investor Relations Hansa Biopharma M: +46 (0) 709–298 269 E: klaus.sindahl@hansabiopharma.com. Katja Margell Head of Corporate Communications Hansa Biopharma M: +46 (0) 768-198 326 E: katja.margell@hansabiopharma.com. About Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com . Katja Margell, Head of Corporate Communications Hansa Biopharma Mobile: +46 (0) 768-198 326 E-mail: katja.margell@hansabiopharma.com Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com.

12 APR 2021 Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference. Register for the webcast. News. 2021-04-08 · This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act. Klaus Sindahl, Head of Investor Relations Hansa Biopharma Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: [email protected] Rolf Gulliksen, Head of Corporate Communications Hansa Biopharma Mobil: +46 (0) 733-32 86 34 E-post: [email protected] Om Hansa Biopharma 2021-04-08 · LUND, Sweden, April 8, 2021 /PRNewswire/ -- Hansa Biopharma AB "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of Antalet röster i Hansa Biopharma uppgår per dagens datum till 44 615 597,7 och aktiekapitalet uppgår till 45 894 909 kronor. För ytterligare information, vänligen kontakta: Klaus Sindahl, Head of Investor Relations Hansa Biopharma Mobil: +46 (0) 709-29 82 69 E-post: klaus.sindahl@hansabiopharma.com Se Soren Tulstrups yrkesprofil på LinkedIn.